SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
哒哒哒
Lv1
40 积分
2023-11-10 加入
最近求助
最近应助
互助留言
6 Years Out, Nivo–Ipi Looks Solid in NSCLC
9小时前
已完结
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
17小时前
已完结
PP01.52 Budget Impact Analysis of Toripalimab Versus Pembrolizumab in Previously Untreated Advanced Squamous NSCLC
1天前
已完结
545P Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
1天前
求助中
1448P First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
1天前
求助中
Outcomes of patients in South Yorkshire with PDL-1 positive or negative locally advanced or metastatic squamous (NSCLC) treated with first line pembrolizumab in combination with carboplatin and paclitaxel
11天前
已完结
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01
11天前
已完结
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results
11天前
已完结
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
13天前
已完结
Durvalumab et tremelimumab en association à la chimiothérapie en première ligne du cancer bronchopulmonaire non à petites cellules (CBNPC) métastatique sans addiction oncogénique
13天前
已关闭
没有进行任何应助
好的 感谢
2个月前
需要补充材料
2个月前
已找到文章【积分已退回】
4个月前
需要的是增补文件哦
5个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论